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Introduction
Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that infects different types of cells 
including T cells, B cells, fibroblasts, dendritic cells and macrophages. Human T-lymphotropic 
virus type 1 infects regulatory T cells that express CD4, CD25 and FOXP3. Human T-lymphotropic 
virus type 1-infected T-regulatory cells have a survival advantage over other infected cells because 
of their ability to suppress the cytotoxic T cells, which normally eradicate HTLV-1 infected cells.1
Human T-lymphotropic virus type 1 is endemic in Southern Japan (with a prevalence of 0% – 
37%), sub-Saharan Africa (with a prevalence of ≤ 5%), the Caribbean region (with a prevalence of 
≤ 6%) and South America (with a prevalence of ≤ 2%).2,3 In South Africa, the prevalence of HTLV-
1 infection among blood donors is < 1%.4
Human T-lymphotropic virus type 1 is transmitted through blood transfusion (cellular and/or 
plasma products), unprotected sex and from mother to baby by vertical transmission. The most 
efficient mode of HTLV-1 transmission is blood transfusion. Transmission of HTLV-1 by blood 
transfusion is more commonly associated with myelopathy or tropical spastic paraparesis, while 
vertical transmission is more commonly associated with the development of Adult T-cell 
leukaemia/lymphoma (ATLL).1
Adult T-cell leukaemia/lymphoma is a rare mature CD4+ T-cell lymphoproliferative neoplasm. 
The first association between ATLL and HTLV-1 infection was reported in 1982 by Hinuma et al.5 
Only 4% – 7% of HTLV-1-infected people will develop ATLL in their lifetime.6
The development of ATLL is a multistep process requiring the accumulation of mutations and 
epigenetic changes. Human T-lymphotropic virus type 1 infection is the first event in this multistep 
process which results in clonal CD4+ T cell proliferation.1,7 There is a long latency period of 20–50 
years from the time of HTLV-1 infection to the development of symptoms of ATLL.1 Given the 
long latency period, ATLL as the name says is a disease occurring in adulthood with a median age 
at diagnosis of 58 years and it is extremely rare in childhood.1,8
In this article, we present a case of an adolescent with ATLL.
Case report
A 17-year-old female, mixed race patient presented to Tygerberg Hospital with complaints of 
abdominal pain, nausea, polyuria and weight loss. On examination, the patient was diagnosed 
with hepatosplenomegaly and an exfoliating rash on her extremities.
This case study explores a clinicopathological presentation of Adult T-cell leukaemia/
lymphoma (ATLL) at Tygerberg Hospital; a disease associated with adulthood noted in an 
adolescent patient. Adult T-cell leukaemia–lymphoma oncogenesis develops through a 
multistep process with an accumulation of mutations. Infection through human T-lymphotropic 
virus type 1 (HTLV-1) is the first step of a multistep process resulting in eventual clonal 
proliferation of mature T-cells. There is a long latency period of 20–50 years from the time of 
infection with HTLV-1 to the development of symptoms of ATLL; thus, ATLL is a malignancy 
associated with adulthood. The median age of diagnosis is 58, ranging from the third to ninth 
decade of life. This is an ideal learning case as it highlights the importance of recognising ATLL 
in children and young adults in our population.
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A full blood count revealed a leucocytosis count of 
286 × 109 cells/L. The peripheral blood smear showed 
lymphocytosis caused by pleomorphic of pleomorphic mature 
atypical lymphocytes (67%) with cloverleaf or ‘flower’ nuclei 
(Figure 1) and absolute eosinophilia (5.9 × 109 cells/L). 
Biochemistry results revealed an elevated lactate dehydrogenase 
(1269 U/L) and hypercalcaemia (4.82 mmol/L), the latter 
explaining her presenting symptoms. The test for human 
immunodeficiency virus (HIV) was negative. The patient had 
renal impairment with elevated creatinine (143 µmol/L) and 
urea (15.8 mmol/L) levels.
Flow cytometry showed the characteristic immunophenotype 
of ATLL: CD2+, CD3+, CD4+, CD8-, CD7- and CD25+. The 
aberrant loss of CD7 and positive CD25 facilitated the 
exclusion of Sézary syndrome, which was the main differential 
diagnosis. The bone marrow was hypercellular with focal 
infiltration by atypical cells. Karyotyping showed a gain of 
chromosome 3 (47, XX, +3). Human T-lymphotropic virus 
type 1 Polymerase Chain Reaction (PCR) was positive. The 
patient was thus diagnosed with ATLL, an atypical 
presentation given her age. A positron emission tomography–
computed tomography scan (PET-CT) revealed stage IV of 
the disease and grade IV hydronephrosis of the right kidney 
secondary to staghorn calculi.
The patient received multi-agent chemotherapy consisting of 
vincristine, cyclophosphamide and doxorubicin in combination 
with zidovudine. Bone marrow examination 3 months later 
showed remission. Positron emission tomography–computed 
tomography scan 6 months later showed complete remission.
Discussion
The age of onset of ATLL differs across geographical regions; 
the median age in Japan is 68 years, while in South America 
it is 40 years.9,10 The epidemiology of ATLL in Africa is 
incompletely described. With two other ATLL cases reported 
in young patients we postulate that there may be a clustering 
of young ATLL patients in South Africa (unpublished data).
Approximately 1% – 5% of children infected through vertical 
transmission will develop ATLL.11 Given the high prevalence 
of HTLV-1 in pregnant women in Japan (0.6% – 5.8%) compared 
FIGURE 1: Flower cells on peripheral blood (arrows).
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to South Africa (0.2%), one would expect higher prevalence of 
young ATLL cases in Japan compared to South Africa.12 
However, ATLL has not been noted to occur in Japan before the 
age of 30 years.10,13 This could be because of the implementation 
of measures to prevent vertical transmission of HTLV-1 in 
Japan. These measures include prenatal screening and the 
avoidance of breast-feeding in women testing positive. Vertical 
transmission in Japan was reduced from 20.3% to 2.5%.11
A study conducted by Bittencourt et al. reported on 24 cases 
of ATLL in patients aged 18 years and younger. The age at the 
time of diagnosis in the majority of this cohort (75%, n = 18 
cases) was between 11 and 18 years. Sixteen (66.6%) of these 
were confirmed to be because of vertical transmission of 
HTLV-1 and one was infected through blood transfusion.14 In 
our patient, blood transfusion was excluded. Mother-to-child 
transmission was the most likely mode of HTLV-1 infection 
in our patient. The pathogenesis of ATLL in the young is not 
fully established. Researchers have hypothesised that it is 
because of the acquisition of HTLV-1 infection at an early age: 
intrauterine, in the birth canal or during breastfeeding, when 
the immune system is much less efficient at producing the 
required T-cell response to HTLV-1 infection.14
Several risk factors for the development of ATLL have been 
proposed.1,9 Among these risk factors, African ancestry, 
expansion of T-regulatory cells following multiple types of 
infections found in low-resource settings, specific human 
leukocyte antigen (HLA) types and a high rate of vertical 
transmission because of absence of preventive measures may 
be contributing factors for the development of ATLL in this 
patient. Our patient was of mixed ancestry and was not 
tested for HLA haplotype.
There are four clinical variants of ATLL according to the 
Shimoyama classification. These are acute, lymphomatous, 
chronic and smouldering variants and are recognised in the 
World Health Organisation Classification of Tumours of 
Haematopoietic and Lymphoid Tissues of 2016 (Table 1).8,15 
The patient described in this case study meets the criteria for 
the acute subtype.
Clinically, the most commonly involved organs are the skin, 
lymph nodes, liver and spleen, all which were involved in our 
patient.10 The most common presenting symptom in the 
young population was skin rash.14 The skin rash is of diverse 
nature including erythematous rash, papules and nodules 
with or without ulceration. The chronic variant is typically 
associated with an exfoliative skin rash.8 Our patient presented 
with polyuria, nausea and abdominal pain as a result of 
hypercalcaemia. Despite fulfilling the diagnostic criteria of 
the acute variant, our patient had an exfoliative skin rash, 
which is typically seen with the chronic variant of ATLL.
Adult T-cell leukaemia–lymphoma has a poor prognosis.15 
Reports show that young patients with ATLL generally have 
a short median survival. In Bittencourt’s study, 15 out of the 
24 cases (63%) had demised within 6 months of diagnosis.10 
The patient in this case-report had bone marrow involvement 
which is an independent poor prognostic marker.16 Despite 
the poor prognosis, the patient was alive, in complete 
remission more than a year after diagnosis.
Conclusions
Although ATLL is a disease of adulthood, it may occur in 
younger patients. The presence of hypercalcaemia, skin rash 
and suggestive peripheral blood findings should trigger an 
investigation for ATLL regardless of age. There is a need for a 
National Registry of ATLL cases in South Africa as such a 
registry could monitor the trends and offer opportunities for 
preventive interventions.
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TABLE 1: Diagnostic criteria for clinical subtypes of adult T-cell leukaemia or 
lymphoma.
Variable Smouldering Chronic Lymphoma Acute
Lymphocyte count (×103/L) < 4 ≥ 4 < 4 High
Flower cells (%) < 5 ≥ 5 ≤ 1 High
Lactate dehydrogenase level ≤ 1.5 times 
ULN
< 2.5 times 
ULN
High High
Calcium level Normal Normal High High
Skin and/or lung involvement ± ± ± ±
Lymph node involvement No ± Yes ±
Spleen or liver involvement No ± ± ±
Central nervous system or bone 
or pleural or ascites
No No ± ±
Source: Adapted from Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours 
of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for 
Research on Cancer (IARC); 2016
ULN, upper limit of normal.
Page 4 of 4 Case Report
http://www.sajo.org.za Open Access
References
1. Qayyum S, Choi JK. Adult T-cell leukemia/lymphoma. Arch Path Lab Med. 
2014;138(2):282–286. https://doi.org/10.5858/arpa.2012-0379-RS
2. Proietti FA, Carneiro-Proietti F, Catalan-Soares BC, Murphy EL. Global epidemiology 
of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058–6068. 
https://doi.org/10.1038/sj.onc.1208968
3. Gonçalves DU, Proietti FA, Ribas JGR, et al. Epidemiology, treatment, and 
prevention of human T-cell leukemia virus type 1-associated diseases. Clin 
Microbiol Rev. 2010;23(3):577–589. https://doi.org/10.1128/CMR.00063-09
4. Vermeulen M, Sykes W, Coleman C, et al. The prevalence of human T-lymphotropic 
virus type 1 & 2 (HTLV-1/2) in South African blood donors. Vox Sang. 
2019;114(5):451–458. https://doi.org/10.1111/vox.12778
5. Hinuma Y, Komoda H, Chosa T, et al. Antibodies to adult T-cell leukemia-virus-
associated antigen (ATLA) in sera from patients with ATL and controls in Japan: A 
nation-wide sero-epidemiologic study. Int J Cancer. 1982;29(6):631–635. https://
doi.org/10.1002/ijc.2910290606
6. Satake M, Yamada Y, Atogami S, Yamaguchi K. The incidence of adult T-cell leukemia/
lymphoma among human T-lymphotropic virus type 1 carriers in Japan. Leuk 
Lymphoma. 2015;56(6):1806–1812. https://doi.org/10.3109/10428194.2014.964700
7. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus 
type I infection. Blood. 1995;86(10):3619–3639. https://doi.org/10.1182/blood.
V86.10.3619.bloodjournal86103619
8. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of 
haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency 
for Research on Cancer (IARC); 2016.
9. Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: A review of 
epidemiological evidence. Front Microbiol. 2012;3:322. https://doi.org/10.3389/
fmicb.2012.00322
10. Nosaka K, Iwanaga M, Imaizumi Y, et al. Epidemiological and clinical features of 
adult T-cell leukemia-lymphoma in Japan, 2010–2011: A nationwide survey. 
Cancer Sci. 2017;108(12):2478–2486. https://doi.org/10.1111/cas.13398
11. Carneiro-Proietti ABF, Amaranto-Damasio MS, Leal-Horiguchi CF, et al. Mother- 
to-child transmission of human T-cell lymphotropic viruses-1/2: What we know, 
and what are the gaps in understanding and preventing this route of infection. J 
Pediatric Infect Dis Soc. 2014;3(Suppl 1):24–29. https://doi.org/10.1093/jpids/
piu070
12. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 
infection. Front Microbiol. 2012;3:388. https://doi.org/10.3389/fmicb.2012.00388
13. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I 
(HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A 
nationwide prospective study in Japan. Blood. 2010;116(8):1211–1219. https://
doi.org/10.1182/blood-2009-12-257410
14. Bittencourt AL, Primo J, De Oliveira MF. Manifestations of the human T-cell 
lymphotropic virus type I infection in childhood and adolescence. J Pediatr (Rio J). 
2006;82(6):411–420. https://doi.org/10.2223/JPED.1573
15. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult 
T-cell leukaemia-lymphoma. Br J Haematol. 1991;79(3):428–437. https://doi.
org/10.1111/j.1365-2141.1991.tb08051.x
16. Takasaki Y, Iwanaga M, Tsukasaki K, et al. Impact of visceral involvements and blood 
cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk 
Res. 2007;31(6):751–757. https://doi.org/10.1016/j.leukres.2006.11.013
